CompletedNot Applicable

Computed Tomography Radiomics-Derived Nomogram for Predicting Early Renal Function Decline After Partial Nephrectomy in Renal Cell Carcinoma: A Multicenter Development/Validation Study

1,437 participantsStarted 2016-01-01

Plain-language summary

The goal of this observational study is to explore the relationship between CT-based radiomics and postoperative renal function changes in patients with localized renal cell carcinoma (RCC) undergoing partial nephrectomy (PN). The main question it aims to answer is: Can a radiomics-clinical nomogram integrating CT-based radiomics features with preoperative and intraoperative clinical variables accurately predict early postoperative renal function decline in patients with localized RCC undergoing PN? Participants already undergoing renal CT examination and scheduled for postoperative renal function testing as part of the routine perioperative care will receive renal function assessment after completing surgical treatment for RCC.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * (1) postoperative pathological confirmation of RCC; (2) preoperative contrast-enhanced CT of the kidney or abdomen. Exclusion Criteria: * (1) absence of corticomedullary, nephrographic, or excretory phase CT sequences; (2) poor-quality CT images unsuitable for analysis; (3) incomplete clinicopathologic data; (4) missing renal function data during postoperative follow-up; (5) unavailable renal function assessment within two weeks before surgery.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

early postoperative renal function decline

Timeframe: within 3 to 24 months postoperatively

Trial details

NCT IDNCT07117786

SponsorFirst Affiliated Hospital of Fujian Medical University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-05-06

View on ClinicalTrials.gov More Renal Cell Carcinoma (RCC) trials